MitoQ for Asthma
(MIMDA Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byAnne E Dixon, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: University of Vermont

Trial Summary

What is the purpose of this trial?

A 14-week, randomized, placebo-controlled, double-masked clinical trial in 40 obese patients with poorly controlled asthma. The intervention is Mitoquinol (MitoQ) versus placebo. The primary aim of this pilot study is to determine if MitoQ improves airway reactivity in obese patients with asthma.

Research Team

Anne E Dixon, MD

Principal Investigator

University of Vermont

Eligibility Criteria

This trial is for obese adults with poorly controlled asthma, diagnosed by a physician and on regular therapy. They must have reactive airways as shown by tests, use their rescue inhaler frequently or have had recent severe symptoms or treatment. Smokers, pregnant women, those using certain drugs or with other significant diseases are excluded.

Inclusion Criteria

My asthma is not well-controlled, based on symptoms or recent emergency care.

I have been on prescribed asthma control medication for over 3 months.

Ability and willingness to provide informed consent

See 4 more

Exclusion Criteria

I had sinus surgery less than 4 weeks ago.

Participant unwilling to withhold marijuana use (inhalation) for the duration of the study

I have been diagnosed with COPD by a doctor.

See 17 more

Treatment Details

Interventions

Mitoquinol (MitoQ) (Mitochondrial Targeted Antioxidant)
Placebo (Other)

Trial OverviewThe study compares Mitoquinol (MitoQ), an antioxidant supplement, to a placebo over 14 weeks to see if it improves lung function in obese patients with asthma. It's randomized and double-masked so neither the participants nor researchers know who gets what until the end.

Participant Groups

2Treatment groups

Active Control

Placebo Group

Group I: MitoQActive Control1 Intervention

MitoQ 40 mg per day for 12 weeks

Group II: PlaceboPlacebo Group1 Intervention

placebo daily for 12 weeks